Valeant’s U.S. Diversified Products Segment in 4Q17 and 2017
In 4Q17, Valeant Pharmaceuticals International’s (VRX) U.S Diversified Products generated revenues of $335 million compared to $398 million in 4Q16, a 16% decline on a YoY (year-over-year) basis.